Simple blood test could transform cancer monitoring
NCT ID NCT06367751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds tumor DNA and whether it reveals treatable genetic changes. They will compare results to patients who did not receive the test to understand its real-world usefulness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ctDNA measurement (liquid biopsy blood test)
- What this could lead to
- If successful, this could show that liquid biopsies are a practical tool for monitoring advanced cancer and identifying treatable genetic changes without invasive tissue biopsies.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve outcomes. The test may not detect all tumors, and results may not always change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
159 people
The number who actually took part.
- Started
-
May 2024
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned OR solid malignant tumors that are locally advanced and inoperable OR solid tumors that are metastatic * No prior treatment for advanced/metastatic disease * Indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician * Patient age 18 years and older * General research consent of the University Hospital Basel Exclusion Criteria: ● Patients with primary brain tumors
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Medical Oncology, University Hospital Basel
Basel, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
- Custom-Built immune cells take aim at a notorious cancer mutation
- Experimental injection SHR-7787 put to the test against advanced solid tumors
- Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
- Can a pill shrink Hard-to-Treat ovarian tumors?
- Oral drug RVU120 put to the test against advanced solid tumors